GLP-1 drugs, such as Novo Nordisk’s Wegovy, have become popular for weight loss among US patients struggling with obesity. Despite significant weight-loss benefits, an analysis of US health insurance claims reveals that these medications may drive healthcare costs higher rather than reducing obesity-related expenses. According to data from Prime Therapeutics, a pharmacy benefits manager, US patients’ average annual medical expenses…